United Kingdom Dupixent Market Size, Share, and COVID-19 Impact Analysis, By Indication (Atopic Dermatitis (AD), Asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Chronic Obstructive Pulmonary Disease (COPD), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and UK Dupixent Market Insights, Industry Trend, Forecasts to 2035

United Kingdom Dupixent Market Forecasts to 2035

• The United Kingdom Dupixent Market Size Was Estimated at USD 291.4 Million in 2024
• The UK Dupixent Market Size is Expected to Grow at a CAGR of around 10.82% from 2025 to 2035
• The UK Dupixent Market Size is Expected to Reach USD 902.3 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the UK Dupixent Market Size is Anticipated to Reach USD 902.3 Million by 2035, Growing at a CAGR of 10.82% from 2025 to 2035. In the UK, the prevalence of moderate-to-severe atopic dermatitis and asthma is on the rise. Additionally, dupixent's growth is being supported by physician endorsement, patient assistance programs, and an evolving biologics infrastructure, as well as expanded indications, strong clinical evidence, and supportive NHS reimbursement policies.

Market Overview

The UK dupixent market involves the sale and distribution of the biologic drug dupilumab, including associated services and stakeholders. Dupixent's market is expanding rapidly, due to its novel mechanism that targets interleukin-4 and interleukin-13, effectively treating Type 2 inflammatory illnesses like atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Recent regulatory approvals for other indications, such as bullous pemphigoid and eosinophilic oesophagitis, have increased the drug's patient base. The market's growth is aided by ongoing research and development initiatives, including clinical studies in new therapeutic areas. The United Kingdom has a considerable market share due to its advanced healthcare infrastructure and rising usage of biologics. The region's high prevalence of illnesses such as asthma and atopic dermatitis fuels demand. The considerable promotional strategies, patient access programs, and collaborations with pharmacies at Sanofi and Regeneron resulted in broad market access. Digital health initiatives also improve patient engagement and adherence, which contribute to dupixent's ability to thrive in existing indications, as well as accelerate growth in many other indications.

Report Coverage

This research report categorizes the market for the UK dupixent market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom dupixent market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United Kingdom dupixent market.

Driving Factors

The major drivers for the dupixent market are the rising UK incidence rates of Type 2 inflammatory diseases, regulatory approvals for additional indications, and positive clinical trial results. Major facilitators for market growth and patient access are improved healthcare systems in the UK, the increased use of biologics, marketing momentum driven by Sanofi and Regeneron, pharmacy collaborations, and digital health service models.

Restraining Factors

The dupixent sector in the UK confronts severe entry obstacles due to expensive biologics R&D expenses. Complex monoclonal antibody production requires specialised infrastructure. Furthermore, stringent regulatory requirements and extensive clinical studies slow market entry, reducing competition and preventing new competitors from entering the market. These factors hamper the dupixent market during the forecast period.

Market Segmentation

The United Kingdom dupixent market share is classified into indication and distribution channel.

• The atopic dermatitis (AD) segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The United Kingdom dupixent market is segmented by indication into atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyps (CRSWNP), chronic obstructive pulmonary disease (COPD), and others. Among these, the atopic dermatitis (AD) segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The high incidence of moderate to severe AD and the drug's demonstrated effectiveness in symptom management. Early indication regulatory approval through positive clinical trial evidence and the widespread and increasing use of the drug by dermatologists and practitioners in UK also substantiate its leading share in the UK biologics market.

• The hospital pharmacies segment held the highest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The United Kingdom dupixent market is segmented by distribution channel into hospital pharmacies, retail pharmacies, and others. Among these, the hospital pharmacies segment held the highest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. Inpatient orders of dupixent for severe asthma and COPD are an important resource. Because of their diverse experience managing complicated biologics, including stringent cold-chain storage and precise dosing requirements, Dupixent has successfully been delivered to patients in desperate times. Relationships with manufacturers such as Sanofi and Regeneron allow eligible access to high-cost medication with concurrent knowledge of the payer reimbursement process. In hospital systems, pharmacists integrate smoothly with healthcare systems designed to coordinate the care of patients requiring intensive care.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom dupixent market and a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer
• Novartis
• Regeneron Pharmaceuticals
• Allergan Plc
• Galderma
• Sanofi Genzyme
• Others

Key Target Audience

• Investors
• Market players
• End-users
• Government Authorities
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at United Kingdom, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom dupixent market based on the below-mentioned segments:

United Kingdom Dupixent Market, By Indication

• Atopic Dermatitis (AD)
• Asthma
• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
• Chronic Obstructive Pulmonary Disease (COPD)
• Others

United Kingdom Dupixent Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others